<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468819</url>
  </required_header>
  <id_info>
    <org_study_id>91552</org_study_id>
    <secondary_id>2006-004153-22</secondary_id>
    <secondary_id>310788</secondary_id>
    <nct_id>NCT00468819</nct_id>
  </id_info>
  <brief_title>A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children</brief_title>
  <official_title>Open-label Multi-center Study of Magnetic Resonance Imaging (MRI) With 0.1 mmol/kg Body Weight (BW) Gadavist (1.0 M) to Assess Pharmacokinetics, Safety and Tolerability in Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical study a contrast agent for magnetic resonance imaging (MRI), which has
      already been approved for application in adults, will be investigated in children and
      adolescents. MRI is a modern and safe examination method without delivering radiation burden
      using magnetic fields to produce cross-sectional images of the human body. A special computer
      program then puts these images together and creates a two or three-dimensional image of the
      inner organs thus facilitating the detection and evaluation of pathological changes. In
      contrast-enhanced MRI a contrast agent is injected into a peripheral vein before the
      examination which results in a stronger contrast in the examined area. Therefore,
      pathological changes can be more easily detected and evaluated compared to non-enhanced MRI.
      The company Bayer HealthCare Pharmaceuticals has developed a contrast agent for MRI called
      Gadavist 1.0 which was first approved in 1998 in Switzerland for MRI of brain and spine.
      Since 2003 Gadavist can also be used in magnetic resonance angiography (MRA) in adults, i.e.
      in the MRI examination of the blood vessels and since 2006 in MRI of liver and kidney
      disease. Gadavist was examined in more than 2,900 adults within the framework of clinical
      studies during development and has been used after its marketing authorization in meanwhile
      more than 600,000 patients. Yet, clinical studies investigating Gadavist have been only
      conducted with adults so far. Diseases requiring MRI examinations, however, often occur in
      children, too. Therefore, many contrast agents are already used on a regular basis in MRI
      examinations of children, some of these contrast agents being authorized already. Within the
      framework of this study the pharmacokinetic characteristics of Gadavist in children or
      adolescents will be investigated, i.e. how the contrast agent is distributed and behaves in
      the body. In addition, safety and tolerability will be evaluated in order to demonstrate that
      Gadavist 1.0 is a safe and well tolerated contrast agent also for children and adolescents.
      Furthermore, the study aims to obtain the dosage recommendation of 0.1 ml per kilogram body
      weight also for this population group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please note that the present study is allocated two study phases, i.e. phase I and phase III.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Clearance Estimates of Gadobutrol by Age Group</measure>
    <time_frame>From injection of Gadobutrol up to 8 hours after injection.</time_frame>
    <description>Total body clearance of Gadobutrol in plasma in L/h after intravenous injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Weight-corrected Plasma Clearance Estimates of Gadobutrol by Age Group</measure>
    <time_frame>From injection up to 8 hours after Gadobutrol injection</time_frame>
    <description>Total body clearance of Gadobutrol in plasma corrected for body weight (L/h/kg) after intravenous injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group</measure>
    <time_frame>From injection up to 8 hours after Gadobutrol injection</time_frame>
    <description>Apparent volume of distribution at steady state expressed in L after intravenous injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Weight-corrected Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group</measure>
    <time_frame>From injection to 8 hours after Gadobutrol injection</time_frame>
    <description>Apparent volume of distribution at steady state corrected for body weight (L/h/kg) after intravenous injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Drug Concentration-time Curve of Gadobutrol by Age Group</measure>
    <time_frame>From injection to 8 hours after Gadobutrol injection</time_frame>
    <description>Area under the concentration versus time curve from zero to infinity after intravenous injection expressed in Âµmol*h/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half Life Estimates of Gadobutrol by Age Group</measure>
    <time_frame>From injection to 8 hours after Gadobutrol injection</time_frame>
    <description>Terminal elimination half-life of Gadobutrol from plasma expressed in h and derived from the terminal slope of the concentration versus time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time (MRT) Estimates of Gadobutrol by Age Group</measure>
    <time_frame>From injection to 8 hours after Gadobutrol injection</time_frame>
    <description>Mean residence time of Gadobutrol in plasma expressed in h.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Excretion of Gadolinium as Percent of Administered Dose</measure>
    <time_frame>up to 6 hours after Gadobutrol injection</time_frame>
    <description>Amount of gadolinium* excreted into urine during the collection interval 0 - 6 h post dose expressed as % of administered dose. *A metallic rare-earth element, used as a contrast medium for magnetic resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Basic Technical Adequacy of Magnetic Resonance (MR) Images for Diagnosis by Age Group</measure>
    <time_frame>Up to 1 hour after Gadobutrol injection</time_frame>
    <description>In the participants the technical adequacy (evaluability) of MR images was assessed on the following 4-point scale (1=not adequate [compromised quality], 2=partially adequate [evaluation possible], 3=adequate despite artifacts, 4=adequate with excellent quality).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Contrast Quality of Post Contrast Images by Age Group</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>In the participants qualitative overall contrast quality of post contrast images was assessed on the following 6-point scale (none, poor, moderate, good, excellent, not assessable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Contrast Lesions by Location and by Age Group</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>Number of lesions on pre-contrast images by organ location and age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Contrast Lesions by Location and by Age Group</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>Number of lesions on post-contrast images by organ location and age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Contrast Delineation of Lesion/Vessel Border by Age Group</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>In the participants pre-contrast delineation of each lesion/vessel border was assessed on the following 5-point scale (no, moderate, good, excellent, not assessable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Contrast Delineation of Lesion/Vessel Border by Age Group</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>In the participants post-contrast delineation of each lesion/vessel border was assessed on the following 5-point scale (no, moderate, good, excellent, not assessable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Contrast Lesion Characterization by Age Group</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>In the participants the internal morphology and structure of each pre-contrast lesion was assessed on the following 4-point scale (1=poor, 2=moderate, 3=good, 4=not applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Contrast Lesion Characterization by Age Group</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>In the participants the internal morphology and structure of each post-contrast lesion was assessed on the following 4-point scale (1=poor, 2=moderate, 3=good, 4=not applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Contrast Enhancement in Lesion/Vessel by Age Group (Given Are Total Numbers of Lesions)</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>In the participants the degree of contrast enhancement in each lesion/vessel was assessed on the following 5-point scale (1=no, 2=moderate, 3=good, 4=excellent, 5=not applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Diagnostic Confidence by Age Group</measure>
    <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
    <description>In the participants the change in diagnostic confidence (additional diagnostic gain by the post-contrast scan) was assessed on the following 3-point scale (1=unchanged, 2=improved, 3=worsened).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol (Gadavist, Gadovist, BAY86-4875)</intervention_name>
    <description>In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection</description>
    <arm_group_label>Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years</arm_group_label>
    <arm_group_label>Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years</arm_group_label>
    <arm_group_label>Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years</arm_group_label>
    <arm_group_label>Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (male/ female) of specific age groups (2-6 years, 7-11 years, 12-17 years)
             who are scheduled to undergo Gadolinium (Gd)-enhanced MRI of brain, spine, liver
             and/or kidneys or Gd-enhanced MRA (single field of view).

        Exclusion Criteria:

          -  Clinically unstable patients (e.g. intensive care unit)

          -  Renal insufficiency

          -  Patients undergoing a relevant change in chemotherapy &lt;/= 48 hours prior to and up to
             24 hours after the administration of Gadovist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <state>ThÃ¼ringen</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>GÃ¶teborg</city>
        <zip>41485</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
    <country>Denmark</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <results_reference>
    <citation>Hahn G, Sorge I, Gruhn B, Glutig K, Hirsch W, Bhargava R, Furtner J, Born M, SchrÃ¶der C, AhlstrÃ¶m H, Kaiser S, Moritz JD, Kunze CW, Shroff M, Stokland E, Trnkova ZJ, Schultze-Mosgau M, Reif S, Bacher-Stier C, Mentzel HJ. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest Radiol. 2009 Dec;44(12):776-83. doi: 10.1097/RLI.0b013e3181bfe2d2.</citation>
    <PMID>19858730</PMID>
  </results_reference>
  <results_reference>
    <citation>Reif S, Schultze-Mosgau M, Sutter G. From adults to children: simulation-based choice of an appropriate sparse-sampling schedule. Paediatr Drugs. 2012 Jun 1;14(3):189-200. doi: 10.2165/11595430-000000000-00000.</citation>
    <PMID>22409261</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2007</study_first_submitted>
  <study_first_submitted_qc>May 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <results_first_submitted>June 10, 2011</results_first_submitted>
  <results_first_submitted_qc>August 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2011</results_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contrast-enhanced MRI</keyword>
  <keyword>MR angiography (MRA) Children 2-17 years</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
        <group group_id="P2">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
        <group group_id="P3">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48">Enrolled participants</participants>
                <participants group_id="P2" count="44">Enrolled participants</participants>
                <participants group_id="P3" count="48">Enrolled participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Received/ Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="46">FAS (Full Analysis Set)</participants>
                <participants group_id="P2" count="44">FAS</participants>
                <participants group_id="P3" count="48">FAS</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Drop-outs (Treatment never received)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
        <group group_id="B2">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
        <group group_id="B3">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="1.46"/>
                    <measurement group_id="B2" value="9.0" spread="1.38"/>
                    <measurement group_id="B3" value="14.7" spread="1.80"/>
                    <measurement group_id="B4" value="9.2" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.49" spread="5.434"/>
                    <measurement group_id="B2" value="33.75" spread="8.956"/>
                    <measurement group_id="B3" value="57.19" spread="14.245"/>
                    <measurement group_id="B4" value="36.48" spread="19.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Clearance Estimates of Gadobutrol by Age Group</title>
        <description>Total body clearance of Gadobutrol in plasma in L/h after intravenous injection.</description>
        <time_frame>From injection of Gadobutrol up to 8 hours after injection.</time_frame>
        <population>Final pharmacokinetics (PK) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Clearance Estimates of Gadobutrol by Age Group</title>
          <description>Total body clearance of Gadobutrol in plasma in L/h after intravenous injection.</description>
          <population>Final pharmacokinetics (PK) analysis set</population>
          <units>L/h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="1.45" upper_limit="3.83"/>
                    <measurement group_id="O2" value="3.28" lower_limit="1.81" upper_limit="5.93"/>
                    <measurement group_id="O3" value="4.90" lower_limit="2.52" upper_limit="7.37"/>
                    <measurement group_id="O4" value="3.24" lower_limit="1.53" upper_limit="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Weight-corrected Plasma Clearance Estimates of Gadobutrol by Age Group</title>
        <description>Total body clearance of Gadobutrol in plasma corrected for body weight (L/h/kg) after intravenous injection.</description>
        <time_frame>From injection up to 8 hours after Gadobutrol injection</time_frame>
        <population>Final PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight-corrected Plasma Clearance Estimates of Gadobutrol by Age Group</title>
          <description>Total body clearance of Gadobutrol in plasma corrected for body weight (L/h/kg) after intravenous injection.</description>
          <population>Final PK analysis set</population>
          <units>L/h/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.09" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.05" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.05" upper_limit="0.10"/>
                    <measurement group_id="O4" value="0.10" lower_limit="0.05" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group</title>
        <description>Apparent volume of distribution at steady state expressed in L after intravenous injection.</description>
        <time_frame>From injection up to 8 hours after Gadobutrol injection</time_frame>
        <population>Final PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group</title>
          <description>Apparent volume of distribution at steady state expressed in L after intravenous injection.</description>
          <population>Final PK analysis set</population>
          <units>L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" lower_limit="3.24" upper_limit="6.33"/>
                    <measurement group_id="O2" value="5.98" lower_limit="4.06" upper_limit="11.69"/>
                    <measurement group_id="O3" value="10.02" lower_limit="5.16" upper_limit="14.12"/>
                    <measurement group_id="O4" value="5.96" lower_limit="3.27" upper_limit="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Weight-corrected Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group</title>
        <description>Apparent volume of distribution at steady state corrected for body weight (L/h/kg) after intravenous injection.</description>
        <time_frame>From injection to 8 hours after Gadobutrol injection</time_frame>
        <population>Final PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight-corrected Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group</title>
          <description>Apparent volume of distribution at steady state corrected for body weight (L/h/kg) after intravenous injection.</description>
          <population>Final PK analysis set</population>
          <units>L/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.20" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.14" upper_limit="0.23"/>
                    <measurement group_id="O3" value="0.18" lower_limit="0.09" upper_limit="0.23"/>
                    <measurement group_id="O4" value="0.20" lower_limit="0.12" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Drug Concentration-time Curve of Gadobutrol by Age Group</title>
        <description>Area under the concentration versus time curve from zero to infinity after intravenous injection expressed in Âµmol*h/L.</description>
        <time_frame>From injection to 8 hours after Gadobutrol injection</time_frame>
        <population>Final PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Drug Concentration-time Curve of Gadobutrol by Age Group</title>
          <description>Area under the concentration versus time curve from zero to infinity after intravenous injection expressed in Âµmol*h/L.</description>
          <population>Final PK analysis set</population>
          <units>Âµmol*h/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="815" lower_limit="494" upper_limit="1167"/>
                    <measurement group_id="O2" value="969" lower_limit="590" upper_limit="2163"/>
                    <measurement group_id="O3" value="1167" lower_limit="925" upper_limit="1808"/>
                    <measurement group_id="O4" value="999" lower_limit="590" upper_limit="1808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half Life Estimates of Gadobutrol by Age Group</title>
        <description>Terminal elimination half-life of Gadobutrol from plasma expressed in h and derived from the terminal slope of the concentration versus time curve.</description>
        <time_frame>From injection to 8 hours after Gadobutrol injection</time_frame>
        <population>Final PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life Estimates of Gadobutrol by Age Group</title>
          <description>Terminal elimination half-life of Gadobutrol from plasma expressed in h and derived from the terminal slope of the concentration versus time curve.</description>
          <population>Final PK analysis set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="1.34" upper_limit="2.30"/>
                    <measurement group_id="O2" value="1.61" lower_limit="1.17" upper_limit="2.62"/>
                    <measurement group_id="O3" value="1.65" lower_limit="1.42" upper_limit="2.23"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.34" upper_limit="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Residence Time (MRT) Estimates of Gadobutrol by Age Group</title>
        <description>Mean residence time of Gadobutrol in plasma expressed in h.</description>
        <time_frame>From injection to 8 hours after Gadobutrol injection</time_frame>
        <population>Final PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT) Estimates of Gadobutrol by Age Group</title>
          <description>Mean residence time of Gadobutrol in plasma expressed in h.</description>
          <population>Final PK analysis set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" lower_limit="1.24" upper_limit="2.77"/>
                    <measurement group_id="O2" value="1.83" lower_limit="1.03" upper_limit="3.37"/>
                    <measurement group_id="O3" value="2.03" lower_limit="1.57" upper_limit="2.99"/>
                    <measurement group_id="O4" value="1.94" lower_limit="1.24" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Excretion of Gadolinium as Percent of Administered Dose</title>
        <description>Amount of gadolinium* excreted into urine during the collection interval 0 - 6 h post dose expressed as % of administered dose. *A metallic rare-earth element, used as a contrast medium for magnetic resonance imaging.</description>
        <time_frame>up to 6 hours after Gadobutrol injection</time_frame>
        <population>Valid for urinary analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion of Gadolinium as Percent of Administered Dose</title>
          <description>Amount of gadolinium* excreted into urine during the collection interval 0 - 6 h post dose expressed as % of administered dose. *A metallic rare-earth element, used as a contrast medium for magnetic resonance imaging.</description>
          <population>Valid for urinary analysis</population>
          <units>percentage of administered dose</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.78" lower_limit="9.19" upper_limit="187.73"/>
                    <measurement group_id="O2" value="92.14" lower_limit="18.96" upper_limit="117.18"/>
                    <measurement group_id="O3" value="95.96" lower_limit="3.48" upper_limit="139.03"/>
                    <measurement group_id="O4" value="94.13" lower_limit="3.48" upper_limit="187.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Basic Technical Adequacy of Magnetic Resonance (MR) Images for Diagnosis by Age Group</title>
        <description>In the participants the technical adequacy (evaluability) of MR images was assessed on the following 4-point scale (1=not adequate [compromised quality], 2=partially adequate [evaluation possible], 3=adequate despite artifacts, 4=adequate with excellent quality).</description>
        <time_frame>Up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Basic Technical Adequacy of Magnetic Resonance (MR) Images for Diagnosis by Age Group</title>
          <description>In the participants the technical adequacy (evaluability) of MR images was assessed on the following 4-point scale (1=not adequate [compromised quality], 2=partially adequate [evaluation possible], 3=adequate despite artifacts, 4=adequate with excellent quality).</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>not adequate (compromised quality)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>partially adequate (evaluation possible)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>adequate despite artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>adequate with excellent quality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Contrast Quality of Post Contrast Images by Age Group</title>
        <description>In the participants qualitative overall contrast quality of post contrast images was assessed on the following 6-point scale (none, poor, moderate, good, excellent, not assessable).</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Contrast Quality of Post Contrast Images by Age Group</title>
          <description>In the participants qualitative overall contrast quality of post contrast images was assessed on the following 6-point scale (none, poor, moderate, good, excellent, not assessable).</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Contrast Lesions by Location and by Age Group</title>
        <description>Number of lesions on pre-contrast images by organ location and age group.</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Contrast Lesions by Location and by Age Group</title>
          <description>Number of lesions on pre-contrast images by organ location and age group.</description>
          <population>FAS</population>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Kidney</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vessel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Contrast Lesions by Location and by Age Group</title>
        <description>Number of lesions on post-contrast images by organ location and age group.</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Contrast Lesions by Location and by Age Group</title>
          <description>Number of lesions on post-contrast images by organ location and age group.</description>
          <population>FAS</population>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Kidney</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vessel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Contrast Delineation of Lesion/Vessel Border by Age Group</title>
        <description>In the participants pre-contrast delineation of each lesion/vessel border was assessed on the following 5-point scale (no, moderate, good, excellent, not assessable).</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Contrast Delineation of Lesion/Vessel Border by Age Group</title>
          <description>In the participants pre-contrast delineation of each lesion/vessel border was assessed on the following 5-point scale (no, moderate, good, excellent, not assessable).</description>
          <population>FAS</population>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Contrast Delineation of Lesion/Vessel Border by Age Group</title>
        <description>In the participants post-contrast delineation of each lesion/vessel border was assessed on the following 5-point scale (no, moderate, good, excellent, not assessable).</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Contrast Delineation of Lesion/Vessel Border by Age Group</title>
          <description>In the participants post-contrast delineation of each lesion/vessel border was assessed on the following 5-point scale (no, moderate, good, excellent, not assessable).</description>
          <population>FAS</population>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Contrast Lesion Characterization by Age Group</title>
        <description>In the participants the internal morphology and structure of each pre-contrast lesion was assessed on the following 4-point scale (1=poor, 2=moderate, 3=good, 4=not applicable).</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Contrast Lesion Characterization by Age Group</title>
          <description>In the participants the internal morphology and structure of each pre-contrast lesion was assessed on the following 4-point scale (1=poor, 2=moderate, 3=good, 4=not applicable).</description>
          <population>FAS</population>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Contrast Lesion Characterization by Age Group</title>
        <description>In the participants the internal morphology and structure of each post-contrast lesion was assessed on the following 4-point scale (1=poor, 2=moderate, 3=good, 4=not applicable).</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Contrast Lesion Characterization by Age Group</title>
          <description>In the participants the internal morphology and structure of each post-contrast lesion was assessed on the following 4-point scale (1=poor, 2=moderate, 3=good, 4=not applicable).</description>
          <population>FAS</population>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Contrast Enhancement in Lesion/Vessel by Age Group (Given Are Total Numbers of Lesions)</title>
        <description>In the participants the degree of contrast enhancement in each lesion/vessel was assessed on the following 5-point scale (1=no, 2=moderate, 3=good, 4=excellent, 5=not applicable).</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Contrast Enhancement in Lesion/Vessel by Age Group (Given Are Total Numbers of Lesions)</title>
          <description>In the participants the degree of contrast enhancement in each lesion/vessel was assessed on the following 5-point scale (1=no, 2=moderate, 3=good, 4=excellent, 5=not applicable).</description>
          <population>FAS</population>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Diagnostic Confidence by Age Group</title>
        <description>In the participants the change in diagnostic confidence (additional diagnostic gain by the post-contrast scan) was assessed on the following 3-point scale (1=unchanged, 2=improved, 3=worsened).</description>
        <time_frame>up to 1 hour after Gadobutrol injection</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
          <group group_id="O4">
            <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
            <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Diagnostic Confidence by Age Group</title>
          <description>In the participants the change in diagnostic confidence (additional diagnostic gain by the post-contrast scan) was assessed on the following 3-point scale (1=unchanged, 2=improved, 3=worsened).</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 6 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
        <group group_id="E2">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 7 to 11 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
        <group group_id="E3">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 12 to 17 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
        <group group_id="E4">
          <title>Gadobutrol (Gadavist, BAY86-4875) - Age 2 to 17 Years</title>
          <description>Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Crystal urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Originally, urine was collected up to 6 hours post injection in patients &gt; 9 years. This was amended to patients of all age groups. As a result, urine was collected in 102 of 138 patients with gadobutrol injection (lowest rate in patients 2-6 years).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

